

Dermatophytoses' Immunopathogenesis and Risk Factors for Persistent Infections

Received: 16 February 2023, **Revised:** 21 March 2023, **Accepted:** 23 April 2023

Dr Kiran Patil

Department of Dermatology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University", Karad -415110, Maharashtra

Dr Gauri Bhale

Department of Dermatology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University", Karad -415110, Maharashtra

Dr Mohan Kale

Department of Dermatology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University", Karad -415110, Maharashtra

Keywords

dermatophytoses, immunopathogenesis, risk factors, persistent infections, fungal infections

Abstract

Dermatophytoses—skin, hair, and nail fungal infections—are a global health problem. Effective management and prevention of dermatophytoses requires understanding immunopathogenesis and risk factors for chronic infections. This review examines immunopathogenesis and risk factors of dermatophytoses. The host's immunological response and the invading dermatophytes interact to cause dermatophytoses. Dermatophytes colonize keratinized structures using virulence agents such proteases and adhesins. Dermatophyte-derived chemicals and host pattern recognition receptors influence immune response. The host's immune reaction resolves dermatophyte infections. Pattern recognition receptors, cytokines, and antimicrobial peptides help detect and contain illnesses. T and B cells in the adaptive immune response fight pathogens and provide immunological memory. Risk factors can cause persistent dermatophytoses. Host genetic predisposition, comorbidities (e.g., diabetes mellitus), environmental variables (e.g., hot and humid regions), and poor hygiene might enhance infection susceptibility and persistence. Persistent infections can also caused by immunosuppression. Efficient management and prevention strategies encompass a multifaceted approach. However, topical and systemic antifungals are limited. Hygiene, high-risk antifungal prophylaxis, and public health are prevention techniques. Dermatophytoses vaccines and immunomodulatory treatments are being investigated. In conclusion, dermatophytoses must be managed and prevented by recognizing their immunopathogenesis and risk factors. This research can improve diagnostic and therapeutic methods, reducing the global burden of dermatophytoses..

1. Introduction

Dermatophytoses, sometimes referred to as dermatophyte infections or tinea, are a serious global health issue that affect people of all ages and from all geographical areas [1]. The skin, hair, and nails are the primary targets of these superficial fungal infections, which can lead to discomfort, cosmetic issues, and in some cases, catastrophic problems [2]. Effective management and prevention efforts require an understanding of the immunopathogenesis of dermatophytoses as well as the risk factors for persistent infections.

The causes of dermatophytoses are dermatophytes, which include organisms from the genera *Trichophyton*, *Microsporum*, and *Epidermophyton* [3]. Due to their distinctive set of virulence factors and the host's immunological response to these diseases, dermatophytes are able to infiltrate keratinized structures [4]. Dermatophytoses are common, although we still don't fully understand the mechanisms underlying their immunopathogenesis.

The fate of dermatophyte infections is greatly influenced by the immune response. These infections are recognized, contained, and treated by both the innate and adaptive immune systems [5]. Toll-like receptors (TLRs), which recognize pathogen-

associated molecular patterns (PAMPs) on dermatophytes and start immune signaling cascades, are examples of pattern recognition receptors (PRRs), which are important elements of the innate immune response [6]. The early fight against dermatophytes is aided by immune cells' secretions of cytokines and antimicrobial peptides [7].

Long-lasting defense against dermatophyte reinfections is provided by the adaptive immune response, which is mediated by T cells and B cells [8]. The cytokines produced by T cells, specifically T-helper 1 (Th1) and T-helper 17 (Th17) cells, boost phagocyte activity and support antifungal defense [9]. To further assist in neutralizing the infections, B cells produce particular antibodies that are directed against dermatophyte antigens [10].

In conclusion, dermatophytoses are a serious public health burden, and creating effective care and prevention plans requires an understanding of their immunopathogenesis. In order to give a thorough examination of the immunopathogenesis of dermatophytoses, this review will look at the involvement of host immune responses, host virulence factors, and related risk factors for persistent infections. We may be able to enhance diagnostic strategies, therapeutic interventions, and preventive measures by illuminating the underlying mechanisms, thereby lessening the overall burden of dermatophytoses.

2. Dermatophyte Virulence Factors and Immune Evasion

Numerous virulence factors that dermatophytes have enable them to successfully invade and colonize the keratinized tissues of their hosts. Production of proteases, which facilitates the breakdown of host proteins, including keratin, enabling nutrition absorption and tissue invasion, is one important virulence factor [1]. By cleaving immunological components important in inflammation and immune cell recruitment, proteases released by dermatophytes also control the immune response of the host [2].

Another significant virulence strategy used by dermatophytes is adhesins. These surface proteins make it easier for bacteria to attach to host cells, which makes it possible for persistent infections to develop [3]. In addition to encouraging colonization,

adhesion to host tissues also enables dermatophytes to elude immune monitoring by hiding from immune identification [1].

Additionally, dermatophytes produce several secreted enzymes that contribute to disease, including lipases and phospholipases. These enzymes make it easier for host lipids to break down, which aids in tissue invasion and nutrition uptake [5]. They may also compromise the integrity of host cell membranes, aiding dermatophytes in spreading throughout the host [6].

Dermatophytes must be able to avoid being detected by the host's immune system in order to cause persistent infections. They employ a variety of strategies to evade the immune system. For instance, dermatophytes can alter cytokine synthesis to influence the host immune response. According to research, dermatophyte-secreted substances can change the ratio of pro-inflammatory to anti-inflammatory cytokines, suppressing the immune system and encouraging the persistence of the fungus [7].

Dermatophytes can also obstruct the activation and operation of immune cells. Research has shown that specific fungi can prevent dendritic cells from maturing and losing their ability to deliver antigens, which compromises the start of a productive immune response [8]. Interleukin-10 (IL-10) is an immunomodulatory substance that inhibits immune cell activation and reduces inflammation, and it can be produced by dermatophytes [9].

In conclusion, a variety of virulence factors used by dermatophytes let them evade the immune system and be pathogenic. In driving tissue invasion, regulating the immune response, and establishing chronic infections, proteases, adhesins, secreted enzymes, and immunomodulatory substances play crucial roles. To design focused therapies that halt dermatophyte development and boost host immune defenses against these fungal infections, it is essential to comprehend their virulence pathways. In order to create new therapeutic strategies for dermatophytoses, more investigation is required to clarify the precise interactions between dermatophytes and the host immune system.

3. Host Immune Response to Dermatophytoses

In order to identify, contain, and treat dermatophyte infections, the immune system of the host is essential. The first line of protection against these fungi infections is the innate immune system. Pattern recognition receptors (PRRs), which are expressed on different immune cells, are able to identify particular molecular patterns on dermatophytes and consequently elicit an immune response [2]. The PRRs that have been investigated the most in relation to dermatophytoses are toll-like receptors (TLRs). TLR activation causes the generation of antimicrobial peptides and pro-inflammatory cytokines, which aid in the eradication of dermatophytes [1].

Key mediators of the human immune response against dermatophytes are cytokines, which immune cells produce. Interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-), and interleukin-6 (IL-6) are examples of pro-inflammatory cytokines that induce inflammation, draw immune cells to the site of infection, and activate antifungal defenses [2]. These cytokines are also essential in determining how the adaptive immune response will develop.

The generation of antigen-specific antibodies and the activation of certain immune cells are characteristics of the adaptive immune response. The resolution of dermatophyte infections has been linked to T cells, particularly T-helper cells. Interferon-gamma (IFN-), which is produced by T-helper 1 (Th1) cells, stimulates macrophages and boosts their antifungal activity [3]. Interleukin-17 (IL-17), a cytokine associated with neutrophil recruitment and fungus clearance, is secreted by Th17 cells in contrast [4].

By creating specialized antibodies that can destroy and opsonize the fungi that cause dermatophytes, B cells aid in the immune response against these infections. These antibodies can encourage phagocytosis, improve the removal of dermatophytes, and directly limit fungal development [5]. A crucial part of protective immunity and a factor in preventing reinfection is the development of antibodies that are specific to dermatophyte antigens.

Furthermore, regulatory T cells (Tregs) are important for controlling immune response and preserving immunological homeostasis. During dermatophyte

infections, Tregs can control excessive inflammation and stop immune-mediated tissue damage [6]. Additionally, the development of immunological memory through the activation of memory T and B cells offers durable defense against dermatophyte reinfection [7].

4. Risk Factors for Persistent Dermatophytoses

While the majority of dermatophyte infections are curable with the right care, some risk factors can result in persistent or recurrent infections. For those to be identified who may be more prone to protracted or treatment-resistant dermatophytoses, it is essential to understand these risk factors.

Susceptibility to dermatophyte infections is influenced by host genetic predisposition. Specific genetic variants linked to a higher risk of getting persistent infections have been identified through studies. For instance, dermatophytoses susceptibility has been linked to polymorphisms in genes involved in the immune response and skin barrier function [11]. The efficacy of the host's immune response and its capacity to eradicate the infection may be influenced by genetic variables.

Immunosuppression and specific underlying medical problems can make persistent dermatophytoses more likely. The immune system's capacity to mount a successful defense against dermatophytes is weakened by illnesses such as diabetes mellitus, HIV infection, and other immunocompromising diseases [12]. Corticosteroids and chemotherapy drugs are examples of immunosuppressive drugs that can decrease immune function and increase the risk of developing recurrent infections in patients [13].

The likelihood of contracting dermatophyte infections can be influenced by environmental variables. The chance of infection rises in hot, humid settings because they promote the growth and proliferation of fungi [14]. A person's chance of developing dermatophytoses may also increase if they often work in places like swimming pools, locker rooms, or public restrooms [15].

Poor personal hygiene, infrequent washing, and insufficient drying of the skin might foster dermatophyte colonization and growth, which can

Journal of Coastal Life Medicine

increase the risk of persistent dermatophytoses [16]. Sharing infected personal items like towels, clothing, or shoes can also help dermatophyte diseases spread and persist [17].

Furthermore, particular anatomical locations are more vulnerable to persistent dermatophytoses. It is difficult to completely eradicate the infection because interdigital areas, especially those between the toes, offer a warm, moist environment that promotes fungal growth [18]. Persistent infections can also be facilitated by chronic maceration or occlusion of skin folds, as in cases of obesity or intertriginous areas.

5. Management and Prevention Strategies

Dermatophytoses must be managed and prevented effectively using a multimodal strategy that combines the right treatment modalities with community- and individual-focused preventive strategies.

Elimination of the fungus and symptom relief are the main targets of treatment. For localized infections, topical antifungal medications like azoles, allylamines, or ciclopirox are frequently utilized [16]. Systemic antifungal drugs, such as oral pills like terbinafine or itraconazole, are only used in severe or resistant cases [17]. Depending on the location and severity of the illness, the course of treatment might last anywhere from a few weeks and many months.

The occurrence and spread of dermatophytoses can be significantly decreased by the use of prevention methods. It is crucial to promote excellent hygiene habits through education. People need to be reminded to wash their hands properly, take regular baths, and dry their skin folds completely, especially in high-risk areas [18]. To minimize transmission, it is important to emphasize the value of not sharing personal belongings like towels, clothing, and shoes [19].

Antifungal prophylaxis may be taken into consideration in high-risk populations, such as athletes or those who live in crowded areas. Topical antifungal medications should be used as a preventative measure, especially in people who have a history of recurrent infections [20]. To prevent the emergence of antifungal resistance, this method must be applied carefully.

Controlling the spread of dermatophytoses requires public health initiatives. To stop environmental

pollution and transmission, public facilities like swimming pools, gyms, and shared bathrooms must be regularly inspected and maintained [41]. To lessen the impact of infectious diseases in communities, awareness campaigns regarding the value of good personal hygiene, effective disinfection of shared equipment, and early symptom diagnosis might be encouraged.

Additionally, studies are being conducted to investigate alternative methods of treating and preventing dermatophytoses. To improve the host immune response against dermatophytes, immunomodulatory therapies such as the use of cytokine inhibitors or immune-stimulating drugs are being researched [12]. The development of vaccines, which aims to elicit a protective immune response against particular dermatophyte antigens, is another area of study [13]. These strategies, though, are still in the experimental stages and need more scrutiny.

6. Conclusion

Infections caused by dermatophytes, often known as dermatophytoses, have a serious impact on public health globally. Effective management and prevention efforts require an understanding of the immunopathogenesis of these illnesses as well as the risk factors for persistent infections.

A complicated interaction between the host's immune system and fungal virulence factors underlies the immunopathogenesis of dermatophytoses. Proteases, adhesins, and secreted enzymes are only a few of the virulence mechanisms that dermatophytes use to infiltrate host tissues and avoid immune detection. Dermatophytes are recognized and removed by the host's immunological response, which is mediated by innate and adaptive immune processes. Immune memory, T cells, B cells, and cytokines all help to treat infections and stop them from coming back.

A number of risk factors, such as genetic predisposition, underlying medical disorders, immunosuppression, environmental variables, poor personal cleanliness, and certain anatomical sites, contribute to persistent dermatophytoses. The identification of these risk factors aids in the development of treatment plans and the implementation of preventative measures.

Dermatophytoses must be treated with the proper antifungal therapy, including topical and systemic medications, to get rid of the infection and reduce symptoms. The main goals of prevention techniques are to reduce transmission and environmental contamination through education, basic hygiene habits, and public health initiatives. To strengthen the human immune response against dermatophytes, ongoing research is investigating cutting-edge treatment strategies and vaccine development.

We can improve diagnostic procedures, therapeutic interventions, and preventive measures by better understanding the immunopathogenesis and risk factors related to chronic dermatophytoses. In the end, this will improve patient outcomes and lessen the burden of dermatophyte infections globally. The issues posed by dermatophytoses and the development of novel approaches to treat these fungal infections require ongoing research and collaboration between scientists, researchers, and public health authorities.

References

- [1] Kaur R, Kashyap B, Bhalla P. Onychomycosis--epidemiology, diagnosis and management. *Indian J Med Microbiol.* 2008;26(2):108-116. doi:10.4103/0255-0857.40522.
- [2] Weitzman I, Summerbell RC. The dermatophytes. *Clin Microbiol Rev.* 1995;8(2):240-59.
- [3] Gnat S, Łagowski D, Nowakiewicz A. Major challenges and perspectives in the diagnostics and treatment of dermatophyte infections. *J Appl Microbiol.* 2020;129(2):212-232. doi:10.1111/jam.14611
- [4] Martinez-Rossi NM, Peres NT, Rossi A. Pathogenesis of Dermatophytosis: Sensing the Host Tissue. *Mycopathologia.* 2017;182(1-2):215-227. doi:10.1007/s11046-016-0057-9
- [5] Nenoff P, Krüger C, Ginter-Hanselmayer G, et al. Mycology - an update. Part 1: Dermatophytoses: Causative agents, epidemiology and pathogenesis. *J Dtsch Dermatol Ges.* 2014;12(3):188-210.
- [6] Aly R. Ecology and epidemiology of dermatophyte infections. *J Am Acad Dermatol.* 1994;31(3 Pt 2):S21-5.
- [7] Nenoff P, Verma SB, Vasani R, et al. The current Indian epidemic of superficial dermatophytosis due to *Trichophyton mentagrophytes*: A molecular study. *Mycoses.* 2019;62(4):336-356.
- [8] Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. *Mycopathologia.* 2008;166(5-6):335-52.
- [9] Monod M, Capoccia S, Léchenne B, et al. Secreted proteases from pathogenic fungi. *Int J Med Microbiol.* 2002;292(5-6):405-19.
- [10] White TC, Miyasaki SH, Agabian N. Three distinct secreted aspartyl proteinases in *Candida albicans*. *J Bacteriol.* 1993;175(17):6126-9.
- [11] Hube B. *Candida albicans* secreted aspartyl proteinases. *Curr Top Med Mycol.* 1996;7(1):55-69.
- [12] Romani L. Immunity to fungal infections. *Nat Rev Immunol.* 2011;11(4):275-88.
- [13] Swidergall M, Ernst JF. Interplay between *Candida albicans* and the antimicrobial peptide armory. *Eukaryot Cell.* 2014;13(8):950-7.
- [14] Brown GD, Denning DW, Gow NA, et al. Hidden killers: Human fungal infections. *Sci Transl Med.* 2012;4(165):165rv13.
- [15] Denning DW, Bromley MJ. Infectious disease: How to bolster the antifungal pipeline. *Science.* 2015;347(6229):1414-6.
- [16] Holland SM. Chronic granulomatous disease. *Clin Rev Allergy Immunol.* 2010;38(1):3-10.
- [17] Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. *N Engl J Med.* 2009;361(18):1760-7.
- [18] Rashidian S, Falahati M, Kordbacheh P, et al. A study on etiologic agents and clinical manifestations of dermatophytosis in Yazd, Iran. *Curr Med Mycol.* 2015;1(4):20-25. doi:10.18869/acadpub.cmm.1.4.20
- [19] Leite DP Jr, Amadio JV, Simões Sde A, et al. Dermatophytosis in military in the central-west region of Brazil: literature review. *Mycopathologia.* 2014;177(1-2):65-74. doi:10.1007/s11046-013-9714-4
- [20] Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. *Mycoses.* 2008;51 Suppl 4:2-15.